HK1014497A1 - Therapeutic uses of bactericidal/permeability increasing protein products - Google Patents

Therapeutic uses of bactericidal/permeability increasing protein products

Info

Publication number
HK1014497A1
HK1014497A1 HK98115810A HK98115810A HK1014497A1 HK 1014497 A1 HK1014497 A1 HK 1014497A1 HK 98115810 A HK98115810 A HK 98115810A HK 98115810 A HK98115810 A HK 98115810A HK 1014497 A1 HK1014497 A1 HK 1014497A1
Authority
HK
Hong Kong
Prior art keywords
bactericidal
protein products
therapeutic uses
increasing protein
permeability increasing
Prior art date
Application number
HK98115810A
Other languages
English (en)
Inventor
Roger G Ii Little
Santoro Helene Gazzano
James Brian Parent
Original Assignee
Xoma Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/030,644 external-priority patent/US5348942A/en
Application filed by Xoma Technology Ltd filed Critical Xoma Technology Ltd
Publication of HK1014497A1 publication Critical patent/HK1014497A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK98115810A 1993-03-12 1998-12-28 Therapeutic uses of bactericidal/permeability increasing protein products HK1014497A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/030,644 US5348942A (en) 1993-03-12 1993-03-12 Therapeutic uses of bactericidal/permeability increasing protein products
US9320293A 1993-07-15 1993-07-15
PCT/US1994/002401 WO1994020128A1 (en) 1993-03-12 1994-03-11 Therapeutic uses of bactericidal/permeability increasing protein products

Publications (1)

Publication Number Publication Date
HK1014497A1 true HK1014497A1 (en) 1999-09-30

Family

ID=26706282

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98115810A HK1014497A1 (en) 1993-03-12 1998-12-28 Therapeutic uses of bactericidal/permeability increasing protein products

Country Status (16)

Country Link
US (3) US5639727A (zh)
EP (2) EP0690720B1 (zh)
JP (3) JPH08509703A (zh)
CN (2) CN1105574C (zh)
AT (1) ATE202482T1 (zh)
AU (1) AU684503B2 (zh)
CA (1) CA2157927C (zh)
DE (1) DE69427582T2 (zh)
DK (1) DK0690720T3 (zh)
ES (1) ES2157981T3 (zh)
GR (1) GR3036686T3 (zh)
HK (1) HK1014497A1 (zh)
MX (1) MX9401807A (zh)
NZ (1) NZ263057A (zh)
PT (1) PT690720E (zh)
WO (1) WO1994020128A1 (zh)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US6214789B1 (en) 1993-03-12 2001-04-10 Xoma Corporation Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
US5627153A (en) * 1994-01-14 1997-05-06 Xoma Corporation Anti-fungal methods and materials
CN1105574C (zh) * 1993-03-12 2003-04-16 爱克索马技术有限公司 杀菌/增强通透性蛋白质产物的治疗用途
AU7175694A (en) * 1993-06-17 1995-01-17 Xoma Corporation Lipopolysaccharide binding protein derivatives
US5770561A (en) * 1993-07-14 1998-06-23 Xoma Corporation Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products
WO1995002414A1 (en) * 1993-07-14 1995-01-26 Xoma Corporation Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products
PT759774E (pt) * 1993-09-22 2002-11-29 Xoma Technology Ltd Metodo para o tratamento de infeccoes bacterianas gram-negativas por administracao de um produto de proteina bactericida indutora da permeabilidade (bip) e de um antibiotico
CN1133634A (zh) * 1993-09-22 1996-10-16 爱克斯欧玛公司 定量体液中的bpi的方法
US6759203B1 (en) 1993-09-22 2004-07-06 Xoma Corporation Method for quantifying BPI in body fluids
DE69527195T2 (de) * 1994-01-14 2003-03-06 Xoma Technology Ltd., Berkeley Anti gram positive bakterielle verfahren und mittel
US5447913A (en) * 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US6271203B1 (en) 1994-07-07 2001-08-07 Xoma Corporation Anti-protozoan methods and materials
US5646114A (en) 1994-07-11 1997-07-08 Xoma Corporation Anti-protozoan methods
EP0824547B1 (en) * 1994-09-15 2003-12-10 XOMA Technology Ltd. Anti-fungal peptides
US5494896A (en) * 1995-03-31 1996-02-27 Xoma Corporation Method of treating conditions associated with burn injuries
AU727085B2 (en) * 1995-07-20 2000-11-30 Xoma Corporation Anti-fungal peptides
WO1997042966A1 (en) 1996-05-10 1997-11-20 Xoma Corporation Therapeutic uses of bpi protein products for human meningococcemia
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
CA2255539C (en) * 1996-05-23 2005-09-27 Xoma Corporation Therapeutic uses of bpi protein products in humans with hemorrhage due to trauma
AU3968597A (en) 1996-08-02 1998-02-25 Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors
US5888973A (en) * 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
US6482796B2 (en) * 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
ATE269699T1 (de) * 1997-10-31 2004-07-15 Childrens Medical Center Methoden zur regulierung der grösse und des wachstums von durchblutetem normalem gewebe
US6264596B1 (en) 1997-11-03 2001-07-24 Meadox Medicals, Inc. In-situ radioactive medical device
US6720311B2 (en) 1997-12-18 2004-04-13 David Tsai Polypeptide for the treatment of cancer and a method for preparation thereof
US6737402B2 (en) 1997-12-18 2004-05-18 David Tsai Method of preparing fetuin to induce apoptosis
US5994298A (en) * 1997-12-18 1999-11-30 Tsai; David Proteins for cancer cell specific induction of apoptosis and method for isolation thereof
US7238662B2 (en) * 1997-12-18 2007-07-03 Ambryx Biotechnology, Inc. Alpha 2HS glycoprotein for treatment of cancer and a method for preparation thereof
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
US6242219B1 (en) * 1999-03-18 2001-06-05 Xoma (Us) Llc Methods for recombinant peptide production
US6515104B1 (en) * 1999-06-25 2003-02-04 Xoma Technology Ltd. Therapeutic peptide-based constructs derived from domain II of bactericidal/permeability-increasing protein
US6964948B2 (en) * 1999-06-25 2005-11-15 Xoma Technology Ltd. Therapeutic peptide-based constructs derived from Domain II of bactericidal/permeability-increasing protein
WO2002055099A2 (en) * 2000-12-01 2002-07-18 Xoma Technology Ltd Modulation of pericyte proliferation using bpi protein products or bpi inhibitors
US7192737B2 (en) 2002-03-29 2007-03-20 Xoma Technology Ltd. Methods and materials for increasing expression of recombinant polypeptides
EP1741440A1 (en) 2005-07-08 2007-01-10 Mellitus S.L. Use of BPI protein for the treatment of disorders of the metabolism and cardiovascular disorders
US8592393B2 (en) 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
ES2567079T3 (es) 2007-11-02 2016-04-19 Momenta Pharmaceuticals, Inc. Composiciones de polisacáridos que no son anticoagulantes
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US9387256B2 (en) 2010-04-16 2016-07-12 Momenta Pharmaceuticals, Inc. Tissue targeting
US10017585B2 (en) 2010-06-17 2018-07-10 Momenta Pharmaceuticals, Inc. Methods and compositions for promoting hair growth
CN103648515B (zh) * 2011-04-05 2018-01-02 达纳-法伯癌症研究所有限公司 作为辐射缓和剂和辐射防护剂的bpi和其同源物
WO2014193818A1 (en) 2013-05-28 2014-12-04 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions
GB201319621D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Antimicrobial agents and their use in therapy
GB201319620D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy
IT201700108102A1 (it) * 2017-09-27 2019-03-27 Univ Degli Studi Padova Composizione di bactericidal/permeability increasing protein e acido ialuronico per il trattamento delle artropatie
WO2019063320A1 (en) 2017-09-27 2019-04-04 Universita' Degli Studi Di Padova COMPOSITION COMPRISING A BACTERICIDE / PERMEABILITY INCREASING PROTEIN AND HYALURONIC ACID FOR THE TREATMENT OF ARTHROPATHIES
EP3566717A1 (en) 2018-05-09 2019-11-13 Universität Regensburg Bactericidal/permeability increasing protein for use in a method of immunization, preferably as an adjuvant in a method of vaccination

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262403A (en) * 1986-03-10 1993-11-16 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II
EP0375724B1 (en) * 1987-08-11 1995-05-31 New York University Biologically active bactericidal/permeability-increasing protein fragments
US5086164A (en) * 1989-01-10 1992-02-04 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
US5112946A (en) * 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5221664A (en) * 1990-04-23 1993-06-22 Magainin Pharmaaceuticals Inc. Composition and treatment with biologically active peptides and toxic cations
EP0541716A1 (en) * 1990-07-27 1993-05-19 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
EP0563222B1 (en) * 1990-12-03 1998-02-25 New York University Biologically active bactericidal/permeability-increasing protein fragments
US5357041A (en) * 1991-12-06 1994-10-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Heparin- and sulfatide-binding peptides from the type I repeats of human thrombospondin
CA2106368A1 (en) * 1992-01-16 1993-07-17 Theodore E. Maione Methods and compositions for treatment of angiogenic disease
US5491130A (en) * 1992-11-10 1996-02-13 The United States Of America As Represented By The Department Of Health And Human Services Peptide inhibitors of fibronectin and related collagen-binding proteins
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
CN1105574C (zh) * 1993-03-12 2003-04-16 爱克索马技术有限公司 杀菌/增强通透性蛋白质产物的治疗用途
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof

Also Published As

Publication number Publication date
CN1124455A (zh) 1996-06-12
JP2005206606A (ja) 2005-08-04
EP1129718A2 (en) 2001-09-05
DK0690720T3 (da) 2001-08-27
GR3036686T3 (en) 2001-12-31
JPH08509703A (ja) 1996-10-15
JP2005187480A (ja) 2005-07-14
WO1994020128A1 (en) 1994-09-15
ATE202482T1 (de) 2001-07-15
CN1478543A (zh) 2004-03-03
US5639727A (en) 1997-06-17
AU684503B2 (en) 1997-12-18
CA2157927A1 (en) 1994-09-15
CA2157927C (en) 1999-03-30
EP1129718A3 (en) 2002-05-22
US5807818A (en) 1998-09-15
ES2157981T3 (es) 2001-09-01
EP0690720A1 (en) 1996-01-10
CN1105574C (zh) 2003-04-16
DE69427582D1 (de) 2001-08-02
PT690720E (pt) 2001-12-28
AU6360594A (en) 1994-09-26
DE69427582T2 (de) 2001-10-04
NZ263057A (en) 2000-12-22
EP0690720B1 (en) 2001-06-27
MX9401807A (es) 1995-01-31
US20020090368A1 (en) 2002-07-11

Similar Documents

Publication Publication Date Title
HK1014497A1 (en) Therapeutic uses of bactericidal/permeability increasing protein products
NZ332721A (en) Use of bactericidal/permeability increasing (BPI) protein sometimes in conjunction with a thrombolytic agent to treat thrombotic disorders
ATE214924T1 (de) Verwendung von nebivolol als anti-atherogenisches mittel
DE69333775D1 (de) Synthetische katalytische freie radikalfänger, verwendbar als antioxidantien zur prävention und therapie von krankheiten
ATE282425T1 (de) Verfahren zur behandlung von endothelialen verletzungen
ATE431364T1 (de) Inhibitoren der menschlichen elastase von neutrophilen
ATE232396T1 (de) Oxydiertes thymosin beta 4
DE69526216D1 (de) Antifungaleverfahren und mitteln
ES2119185T3 (es) Tratamiento de enfermedades micobacterianas por administracion de productos de la proteina bactericida/que aumenta la permeabilidad.
ATE197670T1 (de) Parenterales busulfan zur behandlung von malignen krankheiten
ATE234111T1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
DE69133485D1 (de) Verwendung von Staphylococcus Enterotoxin Homologe für Krebs-Therapie
DK465488D0 (da) Farmaceutisk praeparat indeholdende en triazol-forbindelse
IT8721115A0 (it) Fitopreparato per la cura di affezioni cutanee.
EE04040B1 (et) Aminotetraliini derivaat kardiovaskulaarsete haiguste raviks
IT1288399B1 (it) Medicamento per il trattamento terapeutico della maculopatia legata all'eta', della maculopatia non legata all'eta' e per la profilassi
MXPA01007031A (es) Metodo para tratar enfermedades acrdiacas cronicas.
IL143279A0 (en) Novel therapeutic application of low molecular weight heparin
DK0455769T3 (da) Anvendelse af 7-OH-1,2-benzopyron til fremstilling af et lægemiddel til behandling af magline tumore r hos mennesker
NO912528D0 (no) Behandling av sykdommer forbundet med jodmangel.
ES1022564Y (es) Armonizador electromagnetico de las alteraciones fisiologicas del cuerpo humano.
BG105763A (en) Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
DE69617237D1 (de) Verwendung von imidazo(a,5-a)quinolonen als neuroprotektive arzneimittel

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20060311